Q2 2026 revenue up +27% to €4.1 million
8th consecutive quarter of sustained growth
Balanced growth across both Spine Implants and Medical Equipment businesses in the first half of 2026, with sales of the new JSS hybrid posterior fixation system doubling
BORDEAUX, France & BOSTON, July 07, 2026--(BUSINESS WIRE)--Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announces its revenue for the first half of 2026.
Ludovic Lastennet, IMPLANET's Chief Executive Officer, stated: "With a second quarter marked by sustained growth, the first half of 2026 confirms IMPLANET's strong business momentum, with revenue up 23%, driven by all of our geographic regions and by the commercial success of the new JSS hybrid posterior fixation system, whose sales have doubled over the period. The particularly strong performance in the United States, which became our largest region in the second quarter of 2026, validates the relevance of our commercial investments and our international expansion strategy. At the same time, we continue to strengthen our product offering, notably through technologies developed in partnership with Sanyou Medical and the planned launch of new product lines, to further pursue our growth trajectory."
First-Half 2026 Revenue up +23%
Revenue by Activity (in € thousands – IFRS1) | 2026 | 2025 | Change % |
Total revenue – Q1 | 3,031 | 2,578 | +18% |
Total revenue – Q2 | 4,104 | 3,231 | +27% |
First-half total | |||
Spine Implants | 4,806 | 3,993 | +20% |
Medical Equipment (SMTP) | 2,311 | 1,822 | +27% |
Services (MADISON) | 17 | (6) | - |
Total first-half revenue | 7,134 | 5,809 | +23% |
The Company generated first-half 2026 revenue of €7.13 million, compared with €5.81 million in the same period of 2025. This 23% increase (representing €1.33 million of additional revenue) over the first six months of 2026 confirms the sustained growth achieved in previous periods, marking the Company's eighth consecutive quarter of growth.
The Spine Implants business generated €4.81 million in revenue during the first half of 2026, compared with €3.99 million in the first half of 2025. This performance was primarily driven by the strong commercial success of the new JSS hybrid posterior fixation system, with associated sales doubling year-on-year.
The Company continued to expand its medical equipment distribution business with the SMTP ultrasonic scalpel. Revenue from this activity reached €2.31 million in the first half of 2026, representing +27% growth compared with €1.82 million recorded in the same period of the previous year.